STOCK TITAN
  1. Home
  2. News
  3. MYNZ

Mainz Biomed N.V. Ordinary Shares - MYNZ STOCK NEWS

Welcome to our dedicated page for Mainz Biomed N.V. Ordinary Shares news (Ticker: MYNZ), a resource for investors and traders seeking the latest updates and insights on Mainz Biomed N.V. Ordinary Shares stock.

Mainz Biomed N.V. (symbol: MYNZ) is a pioneering company in the field of molecular genetic diagnostics, dedicated to providing patient-friendly testing solutions for life-threatening conditions. With a mission to improve early detection rates and thereby save lives through science, Mainz Biomed develops market-ready products that are both accurate and easy to use.

One of their key innovations is ColoAlert®, a non-invasive, at-home screening test for colorectal cancer (CRC). Utilizing real-time Polymerase Chain Reaction (PCR) to detect molecular-genetic biomarkers in stool samples, ColoAlert® offers high sensitivity and specificity. This test is available in select European countries and is poised for FDA approval in the United States through the ongoing 'ReconAAsense' clinical trial.

Mainz Biomed aims to expand its market reach by fostering partnerships with laboratories and healthcare providers. The company is also committed to advancing the early detection of other cancers, including pancreatic cancer, through products like PancAlert, which is currently in early stages of development.

Recently, Mainz Biomed showcased ColoAlert® at the UDH Congress, emphasizing its role in enhancing comprehensive health strategies. The company reported a 69% year-over-year revenue increase for ColoAlert® and maintained a stable financial condition with a $7.1 million cash balance at year-end.

In collaboration with healthcare professionals, Mainz Biomed continues to contribute to scientific research and knowledge exchange. This commitment was highlighted by their latest clinical studies, ColoFuture and eAArly DETECT, which demonstrated extraordinary statistical significance in CRC and advanced adenoma detection.

For more details, visit Mainz Biomed's official website at www.mainzbiomed.com.

News

Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees

Rhea-AI Summary
Mainz Biomed N.V. (NASDAQ:MYNZ) partners with Hermann Bantleon GmbH to offer ColoAlert® At-Home Screening Test to employees across all three German locations in Q1 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
-
News

Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland

Rhea-AI Summary
Mainz Biomed N.V. (NASDAQ:MYNZ) actively participates in two significant gastroenterology conferences in Poland alongside TestDNA, showcasing their flagship product ColoAlert® for colorectal cancer detection and emphasizing the need for earlier detection strategies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
none
-
News

Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers

Rhea-AI Summary
Mainz Biomed N.V. (NASDAQ:MYNZ) announced groundbreaking results from its eAArly DETECT U.S. clinical study, reporting a sensitivity for colorectal cancer of 97% with a specificity of 97% and a sensitivity for advanced adenoma of 82%. The study supports the inclusion of novel mRNA biomarkers in a pivotal FDA clinical trial, positioning the next generation ColoAlert® as a robust and accurate at-home CRC diagnostic screening test on the market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.53%
Tags
clinical trial
News

Mainz Biomed’s Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast

Rhea-AI Summary
Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, will present at the 35th Annual Piper Sandler Healthcare Conference. The presentation by CEO Guido Baechler and CFO Bill Caragol will be available for live viewing and post-event webcast. The conference aims to bring together industry executives, investors, and professionals to explore critical trends and identify impactful leaders in the healthcare market. Baechler and Caragol will also be available for 1-on-1 meetings with investors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.82%
Tags
none
-
News

Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference

Rhea-AI Summary
Mainz Biomed N.V. (NASDAQ:MYNZ) announces that its CEO and CFO will present at the 35th Annual Piper Sandler Healthcare Conference in New York, NY, USA. The conference aims to bring together industry executives, investors, and professionals to explore critical healthcare trends. Mainz Biomed's presentation is scheduled for November 29th at 8.50am ET, with opportunities for 1-on-1 meetings with investors throughout the day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.13%
Tags
conferences
-
News

Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Rhea-AI Summary
Mainz Biomed N.V. (NASDAQ:MYNZ) reported a 102% increase in ColoAlert® revenue for the nine months ended September 30, 2023. The company also achieved groundbreaking clinical trial results for ColoFuture study, expanded its network of international commercial partners, and continued preparations for ReconAAsense clinical study. Financially, the company experienced a growth in revenue but an increase in operating loss due to higher sales and marketing and R&D costs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.96%
Tags
earnings
News

Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering

Rhea-AI Summary
Mainz Biomed N.V. (Nasdaq: MYNZ) announced the closing of a $5.0 million registered direct offering with institutional investors to purchase ordinary shares and warrants. The offering was made pursuant to an effective shelf registration statement on Form F-3 declared effective by the SEC. Titan Partners Group, a division of American Capital Partners, acted as the sole placement agent for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
offering
-
News

Mainz Biomed Announces Pricing of $5.0 million Registered Direct Offering

Rhea-AI Summary
Mainz Biomed N.V. (MYNZ) Announces $5.0 Million Registered Direct Offering to Institutional Investors for Molecular Genetics Diagnostic Development
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-46.43%
Tags
offering
-
News

Mainz Biomed Partners with Liquid Biosciences to Harness the Power of Artificial Intelligence (AI) to Develop Next-generation Colorectal Screening Test

Rhea-AI Summary
Mainz Biomed NV (NASDAQ:MYNZ) announced a strategic partnership with Liquid Biosciences to utilize cutting-edge AI analysis platform for clinical trials and cancer screening test processing. The collaboration aims to extend the use of EMERGE to analyze the Company’s ColoFuture study, integrate novel gene expression biomarkers into ColoAlert®, and advance a self-administered CRC screening tool. Liquid Biosciences is widely considered a premier analytical partner to the life sciences industry, and EMERGE's key attributes include computational speed, ability to handle millions of variables, and unbiased methodology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.14%
Tags
partnership AI
News

Mainz Biomed to Showcase ColoAlert® at Leading Global Healthcare Event, MEDICA

Rhea-AI Summary
Mainz Biomed N.V. (NASDAQ:MYNZ) announced that their VP Commercial Operations, Tarrin Khairi-Taraki, will attend MEDICA, a large medical B2B trade fair, to showcase ColoAlert®, the company's flagship product for at-home detection of colorectal cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.45%
Tags
none

FAQ

What is the current stock price of Mainz Biomed N.V. Ordinary Shares (MYNZ)?

The current stock price of Mainz Biomed N.V. Ordinary Shares (MYNZ) is $6.68 as of December 20, 2024.

What is the market cap of Mainz Biomed N.V. Ordinary Shares (MYNZ)?

The market cap of Mainz Biomed N.V. Ordinary Shares (MYNZ) is approximately 12.3M.

What does Mainz Biomed specialize in?

Mainz Biomed specializes in developing molecular genetic diagnostic solutions for early detection of life-threatening conditions, such as colorectal and pancreatic cancers.

What is ColoAlert®?

ColoAlert® is Mainz Biomed's flagship product, a non-invasive, at-home test for colorectal cancer that uses PCR technology to detect molecular-genetic biomarkers in stool samples.

Where is ColoAlert® available?

ColoAlert® is currently available in select European countries and is undergoing FDA approval for the U.S. market.

What recent achievements has Mainz Biomed made?

Mainz Biomed recently presented significant clinical study results at the UDH Congress and reported a 69% year-over-year revenue increase for ColoAlert®.

What is the ReconAAsense trial?

The ReconAAsense trial is Mainz Biomed's FDA-registration study designed to evaluate ColoAlert® for U.S. regulatory approval.

What other products does Mainz Biomed have in development?

Apart from ColoAlert®, Mainz Biomed is developing PancAlert, an early-stage screening test for pancreatic cancer.

How does ColoAlert® differ from other CRC screening tests?

ColoAlert® offers higher accuracy and earlier detection rates compared to traditional fecal occult blood tests (FOBT), thanks to its advanced PCR-based technology.

What is Mainz Biomed’s mission?

Mainz Biomed's mission is to save lives through science by providing accurate, easy-to-use diagnostic solutions for early detection of deadly conditions.

How does Mainz Biomed contribute to the healthcare sector?

Mainz Biomed contributes through scientific research, innovative diagnostic solutions, and partnerships with healthcare professionals to improve early detection and patient care.

Where can I find more information about Mainz Biomed’s investor relations?

For more information on investor relations, visit Mainz Biomed’s official website at www.mainzbiomed.com/investors/.

Stock MYNZ logo
Mainz Biomed N.V. Ordinary Shares

Nasdaq:MYNZ

MYNZ Rankings

#5510 Ranked by Market Cap
N/A Ranked by Dividends

MYNZ Stock Data

12.31M
3.26M
5.8%
0.25%
5.57%
Diagnostics & Research
Healthcare
Link
United States of America
Mainz